Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.45 |
| ▸ | FAP | Q12884 | 2/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658501 | 0.81 | DPP4 (0.65) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL13399328 | 0.81 | DPP4 (0.65) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL15386487 | 0.81 | DPP4 (0.65) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL13263356 | 0.81 | DPP4 (0.45) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL15386493 | 0.80 | DPP4 (0.46) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL15028072 | 0.79 | DPP4 (0.58) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL13285822 | 0.78 | DPP4 (0.64) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL15712090 | 0.77 | DPP4 (0.41) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL8246705 | 0.74 | DPP4 (0.43) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL24440806 | 0.73 | DPP4 (0.56) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885DPP8 21/4885DPP7 19/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885DPP8 21/4885DPP7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.